Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Bria, Emilio; Massari, Francesco; Maines, Francesca; Pilotto, Sara; Bonomi, Maria; Porta, Camillo; Bracarda, Sergio; Heng, Daniel; Santini, Daniele; Sperduti, Isabella; Giannarelli, Diana; Cognetti, Francesco; Tortora, Giampaolo; Milella, Michele
• Is Part Of: Critical reviews in oncology/hematology. Volume 93:Issue 1(2015)
• Page Start: 50
• Page End: 59
• Publication Date: 2015-01
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2014.08.001
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0070"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0210">These data support the use of PFS as a reliable intermediate endpoint for survival benefit in the context of first-line treatment for advanced RCC.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0215">This correlation is far less stringent in the second- and subsequent-lines setting.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0220">Benchmarking and power analyses, on the basis of the updated survival expectations, may represent practical tools for the design of future trials in first-line setting.</p> </list-item> </list> </p> </sec> </abstract>